Document Detail


Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
MedLine Citation:
PMID:  23035244     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The proteins MDM2 and MDM4 are key negative regulators of the tumor suppressor protein p53, which are frequently upregulated in cancer cells. They inhibit the transactivation activity of p53 by binding separately or in concert to its transactivation domain. MDM2 is also a ubiquitin ligase that leads to the degradation of p53. Accordingly, MDM2 and MDM4 are important targets for drugs to inhibit their binding to p53. We found from in silico screening and confirmed by experiment that lithocholic acid (LCA) binds to the p53 binding sites of both MDM2 and MDM4 with a fivefold preference for MDM4. LCA is an endogenous steroidal bile acid, variously reported to have both carcinogenic and apoptotic activities. The comparison of LCA effects on apoptosis in HCT116 p53(+/+) vs. p53(-/-) cells shows a predominantly p53-mediated induction of caspase-3/7. The dissociation constants are in the μM region, but only modest inhibition of binding of MDM2 and MDM4 is required to negate their upregulation because they have to compete with transcriptional coactivator p300 for binding to p53. Binding was weakened by structural changes in LCA, and so it may be a natural ligand of MDM2 and MDM4, raising the possibility that MDM proteins may be sensors for specific steroids.
Authors:
Simon M Vogel; Matthias R Bauer; Andreas C Joerger; Rainer Wilcken; Tobias Brandt; Dmitry B Veprintsev; Trevor J Rutherford; Alan R Fersht; Frank M Boeckler
Related Documents :
24555934 - Production of a monoclonal antibody for c/ebpβ: the subnuclear localization of c/ebpβ...
23349964 - In silico identification of ige-binding epitopes of osmotin protein.
24648494 - Angiomotins link f-actin architecture to hippo pathway signaling.
6136274 - Direct evidence for the presence of selective binding sites for (3h) prostaglandin e2 o...
22370814 - Factor viia binding to endothelial cell protein c receptor: differences between mouse a...
19863064 - Lysine-60 in copper chaperone atox1 plays an essential role in adduct formation with a ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-10-03
Journal Detail:
Title:  Proceedings of the National Academy of Sciences of the United States of America     Volume:  109     ISSN:  1091-6490     ISO Abbreviation:  Proc. Natl. Acad. Sci. U.S.A.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-17     Completed Date:  2012-12-31     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  7505876     Medline TA:  Proc Natl Acad Sci U S A     Country:  United States    
Other Details:
Languages:  eng     Pagination:  16906-10     Citation Subset:  IM    
Affiliation:
Laboratory for Molecular Design and Pharmaceutical Biophysics, Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls University Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Apoptosis / drug effects
Caspase 3 / metabolism
Caspase 7 / metabolism
Cell Line, Tumor
Chromatography, Affinity
Escherichia coli
Fluorescence Polarization
Gene Expression Regulation, Neoplastic / physiology*
Humans
Lithocholic Acid / pharmacology*
Magnetic Resonance Spectroscopy
Nuclear Proteins / antagonists & inhibitors*,  metabolism
Proto-Oncogene Proteins / antagonists & inhibitors*,  metabolism
Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*,  metabolism
Tumor Suppressor Protein p53 / metabolism*
Ultracentrifugation
Chemical
Reg. No./Substance:
0/MDM4 protein, human; 0/Nuclear Proteins; 0/Proto-Oncogene Proteins; 0/Tumor Suppressor Protein p53; 434-13-9/Lithocholic Acid; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspase 7; EC 6.3.2.19/MDM2 protein, human; EC 6.3.2.19/Proto-Oncogene Proteins c-mdm2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised...
Next Document:  Heterogeneity of AMPA receptor trafficking and molecular interactions revealed by superresolution an...